uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis
Univ Med Ctr Hamburg Eppendorf, Inst Clin Chem & Lab Med, Hamburg, Germany.;Karolinska Inst, Dept Mol Med & Surg, Div Clin Chem, Stockholm, Sweden.;Karolinska Univ Hosp, Ctr Mol Med, Stockholm, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Biochemial structure and function.
Univ Med Ctr Hamburg Eppendorf, Clin Dept Hematol & Oncol, Ctr Oncol, Hamburg, Germany..
Karolinska Inst, Dept Mol Med & Surg, Div Clin Chem, Stockholm, Sweden.;Karolinska Univ Hosp, Ctr Mol Med, Stockholm, Sweden..
Show others and affiliations
2015 (English)In: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 126, no 11, 1379-1389 p.Article in journal (Refereed) Published
Abstract [en]

Cancer is a leading cause of thrombosis. We identify a new procoagulant mechanism that contributes to thromboembolism in prostate cancer and allows for safe anticoagulation therapy development. Prostate cancer-mediated procoagulant activity was reduced in plasma in the absence of factor XII or its substrate of the intrinsic coagulation pathway factor XI. Prostate cancer cells and secreted prostasomes expose long chain polyphosphate on their surface that colocalized with active factor XII and initiated coagulation in a factor XII-dependent manner. Polyphosphate content correlated with the procoagulant activity of prostasomes. Inherited deficiency in factor XI or XII or high-molecular-weight kininogen, but not plasma kallikrein, protected mice from prostasome-induced lethal pulmonary embolism. Targeting polyphosphate or factor XII conferred resistance to prostate cancer-driven thrombosis in mice, without increasing bleeding. Inhibition of factor XII with recombinant 3F7 antibody reduced the increased prostasome-mediated procoagulant activity in patient plasma. The data illustrate a critical role for polyphosphate/factor XII-triggered coagulation in prostate cancer-associated thrombosis with implications for anticoagulation without therapy-associated bleeding in malignancies.

Place, publisher, year, edition, pages
2015. Vol. 126, no 11, 1379-1389 p.
National Category
Cardiac and Cardiovascular Systems Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-267337DOI: 10.1182/blood-2015-01-622811ISI: 000363479500019PubMedID: 26153520OAI: oai:DiVA.org:uu-267337DiVA: diva2:873619
Funder
Swedish Cancer Society, 100615Swedish Research Council, K2013-65X-21462-014-5Swedish Heart Lung Foundation, 20140741Stockholm County Council, 20140464German Research Foundation (DFG), SFB877German Research Foundation (DFG), SFB841EU, European Research Council, ERC-StG-2012-311575_F-12
Available from: 2015-11-24 Created: 2015-11-20 Last updated: 2017-12-01Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Ronquist, GöranRonquist, Gunnar

Search in DiVA

By author/editor
Ronquist, GöranRonquist, Gunnar
By organisation
Biochemial structure and function
In the same journal
Blood
Cardiac and Cardiovascular SystemsCancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 273 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf